文献速递临床试验与 GCP基础与转化研究

腺相关病毒基因治疗常染色体隐性耳聋9:单臂试验

AAV gene therapy for autosomal recessive deafness 9: a single-arm trial.
PubMed 文献 · Nat Med · 2025-07-02

在中国5个中心开展的单臂试验中,10例1.5至23.9岁的常染色体隐性耳聋9患者接受Anc80L65衣壳的AAV-OTOF基因治疗,随访6-12个月显示治疗耐受良好,纯音平均听阈从基线106±9 dB改善至52±30 dB,5至8岁儿童疗效最佳。

要点

  • AAV-OTOF基因治疗在1.5至23.9岁患者中耐受良好,共报告162例次I/II级不良事件。
  • 全部10例患者随访至少6个月,纯音平均听阈从基线106±9 dB改善至52±30 dB。
  • 疗效在1个月内快速显现,5至8岁儿童观察至最佳疗效。

核心结论

  • 这些初步结果表明AAV-OTOF在幼儿至成人患者中安全且耐受良好,试验仍在进行中,需要延长随访以确认长期安全性和有效性。

研究设计与样本

  • 在中国5个中心开展的单臂试验,纳入10例1.5至23.9岁的常染色体隐性耳聋9患者,使用Anc80L65衣壳的AAV-OTOF基因治疗,其中1例接受两次注射。
  • 主要终点为5年内的安全性和耐受性,次要终点评估听觉功能,本次报告10例患者随访6-12个月的初步结果。

主要发现

  • 治疗耐受良好,报告162例次I/II级不良事件,中性粒细胞百分比降低为最常见事件(162例次中16例次)。
  • 全部10例患者随访至少6个月,纯音平均听阈从基线106±9 dB(均值±标准差)改善至52±30 dB。
  • 平均短声听性脑干反应阈值从101±1 dB改善至48±26 dB,短纯音听性脑干反应阈值从91±4 dB改善至57±19 dB,听觉稳态反应从80±14 dB改善至64±21 dB。
  • 疗效迅速,1个月即达到总体听力改善的大部分;事后分析显示4个月后短声和短纯音听性脑干反应阈值可可靠预测行为纯音平均阈值(R²分别为0.68、0.73),听觉稳态反应则不能(R²=0.17)。
  • 观察到年龄依赖性疗效,5至8岁儿童结局最佳。

关键数值与推荐

  • 纯音平均听阈从基线106±9 dB改善至52±30 dB。
  • 平均短声听性脑干反应阈值从101±1 dB改善至48±26 dB。
  • 短纯音听性脑干反应阈值从91±4 dB改善至57±19 dB。
  • 听觉稳态反应从80±14 dB改善至64±21 dB。
  • 4个月后短声和短纯音听性脑干反应阈值预测行为纯音平均阈值的R²分别为0.68和0.73,听觉稳态反应为0.17。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出该研究为单臂试验,初步结果需延长随访以确认长期安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gene therapy for congenital deafness has shown promising results in children but lacks data in older populations. We conducted a single-arm trial of adeno-associated virus (AAV)-OTOF gene therapy using the Anc80L65 capsid in ten participants with autosomal recessive deafness 9 aged 1.5 to 23.9 years at five sites in China. The primary endpoints were safety and tolerability within 5 years, and secondary endpoints assessed auditory function. Initial findings from the ten patients with 6-12 months of follow-up, including one patient who received two injections, revealed that the therapy was well tolerated, with 162 grade I/II adverse events. Decreased neutrophil percentage was the most common event (16 of 162). All ten participants had at least 6 months of follow-up and improved their pure-tone-average hearing level from baseline 106 ± 9 (mean ± s.d.) to 52 ± 30 decibels (dB). Other secondary endpoints showed similar improvements, including the average click auditory brainstem response (ABR) threshold, the tone-burst ABR threshold and the auditory steady-state response (101 ± 1 to 48 ± 26 dB, 91 ± 4 to 57 ± 19 dB and 80 ± 14 to 64 ± 21 dB, respectively). Post hoc analyses were conducted to evaluate the timecourse and factors contributing to the hearing improvement. Therapeutic effect was rapid, taking 1 month to achieve most of the overall hearing improvement. On an individual level, click and tone-burst ABR thresholds, but not the auditory steady-state response, reliably predicted the behavioral pure-tone-average thresholds after 4 months (R2 = 0.68, 0.73 and 0.17, respectively). An age-dependent therapeutic effect was observed, with optimal outcomes in 5- to 8-year-olds. These preliminary results show that AAV-OTOF was safe and well tolerated in patients ranging from toddlerhood to adulthood. The trial remains ongoing and requires extended follow-up to confirm the long-term safety and efficacy. ClinicalTrials.gov registration: NCT05901480 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Qi J, Zhang L, Lu L, et al. AAV gene therapy for autosomal recessive deafness 9: a single-arm trial. Nat Med. 2025. PMID: 40603731. doi:10.1038/s41591-025-03773-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。